Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2026)

Mirum Pharmaceuticals' Receivables history runs 6 years deep, the most recent figure standing at $133.1 million for Q1 2026.

• In Q1 2026, Receivables rose 38.87% year-over-year to $133.1 million; the TTM figure through Mar 2026 stood at $133.1 million (up 38.87% YoY), while the FY2025 annual figure was $123.3 million, up 57.54% from the prior year.
• Receivables was $133.1 million for Q1 2026 at Mirum Pharmaceuticals, up from $123.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $133.1 million in Q1 2026 to a low of $7.9 million in Q1 2022.
• Historically, Receivables has averaged $62.7 million across 5 years, with a median of $60.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Receivables soared 3984.25% in 2022, then grew 15.18% in 2024.
• A 5-year view of Receivables shows it stood at $24.0 million in 2022, then jumped by 183.27% to $68.0 million in 2023, then grew by 15.18% to $78.3 million in 2024, then surged by 57.54% to $123.3 million in 2025, then advanced by 7.93% to $133.1 million in 2026.
• The last three Receivables figures came in at $133.1 million (Q1 2026), $123.3 million (Q4 2025), and $107.1 million (Q3 2025), per Business Quant data.